Inogen, Inc. — Q2 2014 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2014. Amounts are in U.S. dollars; financial statement figures are in millions unless stated otherwise. Inogen develops, manufactures and markets portable oxygen concentrators and earns revenue from product sales and rentals.
Financial performance
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Sales revenue | $20.5 | $12.8 | $35.3 | $21.6 |
| Rental revenue | $9.9 | $7.4 | $18.7 | $14.3 |
| Total revenue | $30.4 | $20.2 | $54.0 | $35.9 |
| Gross profit | $15.1 | $11.1 | $27.1 | $19.2 |
| Gross margin | 49.7% | 54.9% | 50.1% | 53.4% |
| Operating income | $4.0 | $2.4 | $5.5 | $3.0 |
| Net income | $2.3 | $2.0 | $3.2 | $2.7 |
| Adjusted EBITDA (non-GAAP) | $7.4 | $4.4 | $11.8 | $6.9 |
- Growth: Q2 revenue rose 50.8% year over year; six-month revenue increased 50.5%. Management attributed sales growth to greater direct-to-consumer activity and business-to-business sales. Rental patients grew to approximately 25,100 from 18,100 a year earlier. Systems sold were approximately 9,200 in Q2 versus 5,500, and 15,500 for the six months versus 9,100.
- Margins: Total gross margin declined as rental margin fell to 53.7% in Q2 from 64.4%, and to 53.2% for the six months from 64.4%. Management cited Medicare competitive-bidding reimbursement cuts and higher rental asset, service and logistics costs. Six-month sales margin improved to 48.4% from 46.2%, helped by lower product costs and a greater direct-to-consumer mix; Q2 sales margin declined to 47.8% from 49.3%, reflecting lower average selling prices.
- Taxes and earnings: Q2 and six-month effective tax rates were 39.5% and 39.4%, respectively, compared with 3.8% and 3.9% in the prior-year periods. The filing attributes the difference principally to the prior-year deferred-tax valuation allowance and its release in December 2013, which generated a one-time tax benefit. Six-month basic and diluted EPS were each reported as $0.13; Q2 basic EPS was $0.13 and diluted EPS $0.11.
- Cash flow and liquidity: Six-month operating cash flow was $8.2 million, versus $6.9 million. Investing cash use was $7.5 million, including $6.8 million for rental equipment; financing provided $54.9 million, principally from the IPO. Cash and cash equivalents were $69.0 million at June 30, 2014, versus $13.5 million at year-end 2013. Current assets were $97.7 million and current liabilities $26.3 million.
- Debt: Total debt was $13.4 million, including $7.1 million current and $6.3 million long-term; the filing identifies $12.7 million in bank financing and $0.7 million in patent-licensing debt. The company reported compliance with its debt covenants at June 30, 2014.
Material changes and significant events
- In February 2014, Inogen completed its IPO, selling 3,529,411 newly issued shares at $16 per share. The company reported approximately $49.7 million in net proceeds after underwriting discounts and expenses. Preferred shares converted to common stock; 18,240,043 common shares were outstanding at June 30.
- Sales and marketing expense rose 38.1% in the first half, while general and administrative expense rose 27.0%. Management cited added personnel, marketing investment, public-company costs and a one-time lender fee. Operating expenses increased more slowly than revenue as a percentage of revenue.
- Accounts receivable increased to $15.6 million from $10.2 million at year-end. Management linked operating cash flow pressure to slower collection of rental receivables; the filing also reports increased rental-revenue adjustment provisions.
Outlook, risks and contingencies
- Management expects available cash, borrowing availability and expected operating cash generation to fund projected operating and investing needs for at least the next 12 months. It plans continued investment in sales and marketing, product development and rental equipment; it did not provide specific revenue or earnings guidance.
- Management stated that a proposed CMS reimbursement approach, if implemented in its then-current form, could reduce 2016 revenue by approximately 4%–5%. Existing competitive-bidding rate reductions have already pressured rental margins. Medicare service reimbursement programs accounted for 25.0% of six-month total revenue.
- Key risks include reimbursement and claims-review changes, collection delays, reliance on government and private payors, competition, and dependence on a limited number of suppliers for key components. The filing also identifies product-liability, regulatory, cybersecurity, intellectual-property and public-company compliance risks.
- Inogen’s patent-infringement lawsuit against Inova Labs remained stayed pending patent reexaminations. The company said it did not anticipate material impact from this or other ordinary-course proceedings. The filing discusses potential healthcare fraud-and-abuse and HIPAA penalties, among other regulatory exposures.
- The company stated disclosure controls were effective as of June 30, 2014 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether rental-margin pressure and CMS competitive-bidding proposals affect reimbursement, rental profitability and the stated potential 2016 revenue reduction.
- Whether the increase in receivables and rental adjustments is followed by improved collections and cash conversion.
- How sales growth, channel mix and pricing affect gross margins, particularly given the difference between Q2 and first-half sales margins.
- Debt maturities, covenant headroom and continued funding needs for rental equipment and other capital investment.
- Developments in the Inova Labs patent case, regulatory and payor audits, and continuity of supply from major component vendors.